Header Logo

Connection

WOLFGANG WINKELMAYER to Treatment Outcome

Back to Details
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Treatment Outcome.
WOLFGANG WINKELMAYER
Connection Strength
1.636
Treatment Outcome
  1. Prospectively Examining Outcomes After Living Kidney Donation: Informing the Altruist. JAMA. 2024 07 23; 332(4):285-286.
    View in: PubMed
    Score: 0.077
  2. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024 07; 106(1):145-153.
    View in: PubMed
    Score: 0.076
  3. The Association of Pre-Kidney Transplant Dialysis Modality with de novo Posttransplant Heart Failure. Cardiorenal Med. 2021; 11(5-6):209-217.
    View in: PubMed
    Score: 0.063
  4. Trends in the Medical Complexity and Outcomes of Medicare-insured Patients Undergoing Kidney Transplant in the Years 1998-2014. Transplantation. 2019 11; 103(11):2413-2422.
    View in: PubMed
    Score: 0.056
  5. De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. Am J Kidney Dis. 2018 08; 72(2):223-233.
    View in: PubMed
    Score: 0.050
  6. Kidney Transplantation Rates Across Glomerulonephritis Subtypes in the United States. Transplantation. 2017 10; 101(10):2636-2647.
    View in: PubMed
    Score: 0.048
  7. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis. Nephrol Dial Transplant. 2017 May 01; 32(5):862-869.
    View in: PubMed
    Score: 0.047
  8. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis. J Nephrol. 2017 Apr; 30(2):281-288.
    View in: PubMed
    Score: 0.044
  9. Kidney Transplantation Outcomes across GN Subtypes in the United States. J Am Soc Nephrol. 2017 02; 28(2):632-644.
    View in: PubMed
    Score: 0.044
  10. Correlates of poor glycemic control among patients with diabetes initiating hemodialysis for end-stage renal disease. BMC Nephrol. 2015 Dec 09; 16:204.
    View in: PubMed
    Score: 0.043
  11. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis. 2015 Oct; 66(4):677-88.
    View in: PubMed
    Score: 0.041
  12. Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol. 2015 Jul 07; 10(7):1170-8.
    View in: PubMed
    Score: 0.041
  13. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
    View in: PubMed
    Score: 0.041
  14. Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis. J Am Heart Assoc. 2014 Oct 21; 3(5):e001356.
    View in: PubMed
    Score: 0.039
  15. Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol. 2013 Aug; 8(8):1336-42.
    View in: PubMed
    Score: 0.036
  16. Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens. 2012 Nov; 21(6):600-6.
    View in: PubMed
    Score: 0.034
  17. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis. 2012 Sep; 60(3):473-86.
    View in: PubMed
    Score: 0.033
  18. Use of secondary prevention medications among adults with reduced kidney function. Clin J Am Soc Nephrol. 2012 Apr; 7(4):604-11.
    View in: PubMed
    Score: 0.033
  19. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2662-8.
    View in: PubMed
    Score: 0.032
  20. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J. 2011 Aug; 162(2):324-30.
    View in: PubMed
    Score: 0.031
  21. Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol. 2011 Jul; 6(7):1794-801.
    View in: PubMed
    Score: 0.031
  22. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis. 2011 Sep; 58(3):409-17.
    View in: PubMed
    Score: 0.031
  23. The effect of altitude change on anemia treatment response in hemodialysis patients. Am J Epidemiol. 2011 Apr 01; 173(7):768-77.
    View in: PubMed
    Score: 0.030
  24. Chronic on acute renal failure: long-term implications of severe acute kidney injury. JAMA. 2009 Sep 16; 302(11):1227-9.
    View in: PubMed
    Score: 0.028
  25. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008 Nov 24; 168(21):2368-75.
    View in: PubMed
    Score: 0.026
  26. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1415-22.
    View in: PubMed
    Score: 0.025
  27. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008 Jul; 19(7):1389-95.
    View in: PubMed
    Score: 0.025
  28. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008 Apr 01; 51(13):1247-54.
    View in: PubMed
    Score: 0.025
  29. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. Int J Cardiol. 2008 Apr 10; 125(2):172-7.
    View in: PubMed
    Score: 0.024
  30. Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart. 2007 Aug; 93(8):945-51.
    View in: PubMed
    Score: 0.023
  31. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant. 2006 Dec; 21(12):3559-66.
    View in: PubMed
    Score: 0.023
  32. Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients. Kidney Int. 2005 May; 67(5):1980-5.
    View in: PubMed
    Score: 0.020
  33. Effects of dialysate potassium concentration of 3.0?mmol/l with sodium zirconium cyclosilicate on?dialysis-free days versus dialysate potassium?concentration of 2.0 mmol/l alone on?rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia. Kidney Int. 2025 Jan; 107(1):169-179.
    View in: PubMed
    Score: 0.020
  34. C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant. 2004 Jul; 4(7):1148-54.
    View in: PubMed
    Score: 0.019
  35. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022 12 06; 146(23):1735-1745.
    View in: PubMed
    Score: 0.017
  36. Diseases of the Aorta and Kidney Disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Cardiovasc Res. 2022 09 20; 118(12):2582-2595.
    View in: PubMed
    Score: 0.017
  37. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002 Sep-Oct; 22(5):417-30.
    View in: PubMed
    Score: 0.017
  38. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Am Heart J. 2021 05; 235:1-11.
    View in: PubMed
    Score: 0.015
  39. Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study. Sci Rep. 2020 04 06; 10(1):5964.
    View in: PubMed
    Score: 0.014
  40. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 05; 95(5):1027-1036.
    View in: PubMed
    Score: 0.013
  41. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 02; 95(2):268-280.
    View in: PubMed
    Score: 0.013
  42. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 02; 95(2):281-295.
    View in: PubMed
    Score: 0.013
  43. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018 12; 94(6):1053-1068.
    View in: PubMed
    Score: 0.013
  44. Market Consolidation and Mortality in Patients Initiating Hemodialysis. Value Health. 2019 01; 22(1):69-76.
    View in: PubMed
    Score: 0.013
  45. Implantable Ventricular Assist Device Use and Outcomes in People With End-Stage Renal Disease. J Am Heart Assoc. 2018 07 06; 7(14).
    View in: PubMed
    Score: 0.013
  46. Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study. Am J Kidney Dis. 2018 10; 72(4):547-559.
    View in: PubMed
    Score: 0.013
  47. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving?Global Outcomes (KDIGO) Controversies?Conference. Kidney Int. 2018 03; 93(3):545-559.
    View in: PubMed
    Score: 0.012
  48. Drug-Eluting Stents Versus Bare Metal Stents for Percutaneous Coronary Intervention in Kidney Transplant Recipients. Transplantation. 2017 Apr; 101(4):851-857.
    View in: PubMed
    Score: 0.012
  49. Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. J Cardiovasc Electrophysiol. 2017 01; 28(1):39-48.
    View in: PubMed
    Score: 0.011
  50. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017 06; 103(11):818-826.
    View in: PubMed
    Score: 0.011
  51. Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. Trials. 2016 08 12; 17:401.
    View in: PubMed
    Score: 0.011
  52. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related?Quality of Life in Patients Receiving?Hemodialysis. Am J Kidney Dis. 2016 Feb; 67(2):271-82.
    View in: PubMed
    Score: 0.011
  53. Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials. 2015 Aug 19; 16:364.
    View in: PubMed
    Score: 0.010
  54. Provider visit frequency and vascular access interventions in hemodialysis. Clin J Am Soc Nephrol. 2015 Feb 06; 10(2):269-77.
    View in: PubMed
    Score: 0.010
  55. Comparison of Medicare claims versus physician adjudication for identifying stroke outcomes in the Women's Health Initiative. Stroke. 2014 Mar; 45(3):815-21.
    View in: PubMed
    Score: 0.009
  56. Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):157-62.
    View in: PubMed
    Score: 0.009
  57. Coronary artery bypass graft type and outcomes in maintenance dialysis. J Cardiovasc Surg (Torino). 2015 Jun; 56(3):463-71.
    View in: PubMed
    Score: 0.009
  58. Near-term prediction of sudden cardiac death in older hemodialysis patients using electronic health records. Clin J Am Soc Nephrol. 2014 Jan; 9(1):82-91.
    View in: PubMed
    Score: 0.009
  59. Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis. Clin J Am Soc Nephrol. 2013 Dec; 8(12):2213-20.
    View in: PubMed
    Score: 0.009
  60. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med. 2013 Jun; 126(6):541.e1-541.e14.
    View in: PubMed
    Score: 0.009
  61. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011 Jun; 63(6):1681-8.
    View in: PubMed
    Score: 0.008
  62. Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors: challenges in comparative effectiveness using Medicare data. Clin Pharmacol Ther. 2011 May; 89(5):674-82.
    View in: PubMed
    Score: 0.008
  63. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation. 2009 Dec 27; 88(12):1377-85.
    View in: PubMed
    Score: 0.007
  64. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
    View in: PubMed
    Score: 0.007
  65. Educational level as a determinant of access to and outcomes after kidney transplantation in the United States. Am J Kidney Dis. 2008 May; 51(5):811-8.
    View in: PubMed
    Score: 0.006
  66. Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol. 2007 Aug; 22(8):1189-93.
    View in: PubMed
    Score: 0.006
  67. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int. 2007 Mar; 20(3):247-55.
    View in: PubMed
    Score: 0.006
  68. Long-term patient and graft survival in the eurotransplant senior program: a single-center experience. Transplantation. 2005 Sep 15; 80(5):582-9.
    View in: PubMed
    Score: 0.005
  69. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol. 2002 Jul; 55(7):711-6.
    View in: PubMed
    Score: 0.004
  70. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol. 2000 Jun; 11(6):1106-1116.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.